SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

TSC-101

TCRX·TScan Therapeutics, Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 3 (paused)
Time to market
Uncertain. The Phase 3 trial is paused due to insufficient capital, and the company is seeking a partner to continue development. Even if partnered, a pivotal trial would need to complete before any regulatory filing, putting potential approval years away.
Why 3/10
No hard, dated catalyst is scheduled for TSC-101 in the next ~12 months. The Phase 3 ALLOHA-2 trial was paused in September 2026 due to insufficient capital, and the company is seeking a partner. Without a pending PDUFA, pivotal readout, or AdComm, the impact score cannot exceed 5 per the rubric.
Actionable Insight BEARISH

TSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.

Price Chart

Loading chart...

Executive Summary

TSC-101 is TScan Therapeutics' lead TCR-T cell therapy for acute myeloid leukemia and myelodysplastic syndromes. It showed promising Phase 1 data in June 2026 and entered a Phase 3 pivotal trial in July 2026. However, in September 2026, TScan cut 75% of its workforce, paused the Phase 3 ALLOHA-2 trial, and pivoted to preclinical solid tumor programs, citing insufficient capital. The stock trades around $0.16 with a ~$11.5M market cap. Multiple analysts downgraded the stock in September 2026. TSC-101's future now depends on the company finding a partner to continue development.

How It Works

TSC-101 is an engineered T cell receptor (TCR) therapy. It takes a patient's or donor's immune T cells and genetically modifies them to recognize the HA-2 antigen, a protein found on the surface of blood cancer cells (acute myeloid leukemia and myelodysplastic syndromes). The modified cells are infused into the patient after a bone marrow transplant to seek out and destroy residual cancer cells while leaving healthy tissue alone.

Trial Status

TSC-101 completed Phase 1 ALLOHA trial with positive data from Cohort C in June 2026 (11 of 14 patients achieved complete donor chimerism within ~3 weeks). The Phase 3 ALLOHA-2 pivotal trial began dosing in July 2026, but enrollment was paused in September 2026 when TScan announced a strategic reorganization cutting 75% of its workforce and shifting focus to solid tumor programs. The company is actively seeking partnerships for the heme program including TSC-101.

The Two-Sided Case

▲ Bull Case4
Phase 1 data were strong: 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, and all 5 patients assessed after a second infusion also achieved complete chimerism.
The FDA agreed on the pivotal study design for TSC-101, reducing regulatory risk if a partner picks up the program.
The company has $73M in cash extending into Q4 2027, providing time to find a partner for the heme program.
Institutional holders like Vanguard ($790K position) and Renaissance Technologies ($380K) remain invested as of Q3 2026.
▼ Bear Case6
The Phase 3 ALLOHA-2 trial is paused due to insufficient capital, with no guarantee a partner will be found to fund completion.
TScan cut 75% of its workforce and the CEO stated the company is 'pausing further development in the heme program', effectively deprioritizing TSC-101.
Three analysts downgraded the stock in early September 2026 (Needham to Hold, Wedbush to Neutral, HC Wainwright to Neutral).
The Amgen collaboration was terminated in August 2026, eliminating a key revenue source; Q3 2026 revenue fell 76% YoY to $0.6M.
Stock trades near $0.16, down from a 52-week high of $1.47, reflecting severe loss of investor confidence.
Stockholders' equity collapsed from $123M at year-end 2025 to $38M by September 30, 2026.

Upcoming Catalysts

  • Partnership or licensing deal for the heme program (including TSC-101)
  • Potential restart of Phase 3 ALLOHA-2 enrollment if partnered

Source Filing

The SecBot filing or press-release report that triggered this drug report:

TScan Therapeutics, Inc. 8-K TCRX ·Originating report

Sources · 5

Hover a chip for the title
1 fiercebiotech.com2 markets.businessinsider.com3 sec.gov4 genengnews.com5 rttnews.com